vedolizumab · Entyvio
Monoclonal antibody
Also known as MLN0002
Evidence outlook
Approved: Crohn's Disease, Ulcerative Colitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (6)
- Adults with moderate to severe active ulcerative colitis or Crohn's disease with inadequate response, loss of response or intolerance to conventional therapy or TNFa inhibitors
- Adults with moderately to severely active Crohn's disease
- Moderately to severely active ulcerative colitis
- ENTYVIO® (vedolizumab) is indicated for: Ulcerative Colitis (Adults ≥ 18 years) the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a tumor necrosis factor-alpha (TNFα) antagonist. Crohn's Disease (Adults ≥ 18 years) the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an...
- Moderately to severely active ulcerative colitis and Crohn's disease
- Moderately to severely active ulcerative colitis and Crohn's disease in adults (chronic pouchitis added later)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
GEMINI II NCT00783692 · Crohn's Disease Design is strong (randomized, triple-blind, placebo-controlled, large adequately powered N=1115, hard clinical endpoint of CDAI-based remission), but per the mixed/partially-met test in the moderate definition, one of three co-primary endpoints (induction enhanced clinical response) missed significance while the others met it, so the overall primary endpoint result is discordant/mixed rather than a clean 'met' -- good design cannot upgrade a mixed result to strong. Registry: NCT00783692 | 3 | Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6; Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6 (Baseline and Week 6); Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52 2012-03 | Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6 (Week 6): Placebo 6.8% (95% CI 2.7-10.8) vs DB Vedolizumab 14.5% (95% CI 9.9-19.2); p=0.0206 (Placebo vs DB Vedolizumab) | Partial signal | link ↗ |
View 7 more trials
GEMINI III NCT01224171 · Crohn's Disease Design meets top-tier criteria (randomized, triple-blind, placebo-controlled, adequately powered, hard clinical endpoint), but the pre-specified primary endpoint comparison was not statistically significant (p=0.4332), which per the grading rules caps a well-designed but null/mixed primary result at 'moderate'. Registry: NCT01224171 | 3 | Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation (Week 6) 2012-02 | Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation (Week 6): Placebo 12.1% (95% CI 7.0-17.2) vs Vedolizumab 15.2% (95% CI 9.6-20.8); p=0.4332 (Placebo vs Vedolizumab) | Partial signal | link ↗ |
NCT02611817 NCT02611817 · Crohn's Disease Randomized, quadruple-blinded, placebo-controlled, adequately powered (n=409 randomized into maintenance phase) design with a primary endpoint (CDAI-based clinical remission, a hard clinical endpoint) that met statistical significance in the favorable direction (p=0.008). Registry: NCT02611817 | 3 | Percentage of Participants Achieving Clinical Remission at Week 52 2019-05-06 | Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC) | Reliable signal | link ↗ |
NCT02425111 NCT02425111 · Crohn's Disease Single-group allocation, no masking, and no comparator arm mean there is no randomization or blinding to isolate drug effect from natural history/placebo response; this is a single-arm open-label design, not a confirmed extension of a prior RCT (no explicit linkage stated), so it defaults to weak despite the hard endoscopic endpoint and large-ish n. Registry: NCT02425111 | 3 | Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26 2017-06-02 | Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26 (Week 26): Vedolizumab 300 mg 11.9% (95% CI 6.3 to 19.8) | Weak signal | link ↗ |
NCT02620046 NCT02620046 · Colitis, Ulcerative, Crohn's Disease This open-label extension gave subcutaneous vedolizumab to 746 patients with ulcerative colitis or Crohn's disease from earlier vedolizumab trials for up to about 8 years. Its primary outcome was the rate of adverse events, a safety measure with no comparator test, so no result can be called met or missed. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Number of Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT02620046 | 3 | Number of Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment (Up to 97.9 months) 2024-06-12 | Open-label long-term extension of vedolizumab SC 108 mg, 288 UC and 458 CD patients, up to 97.9 months: treatment-emergent adverse events 22.9 and 28.0 per 100 patient-years; serious 6.5 and 8.7 per 100 patient-years. Safety primary with no formal test. | Weak signal | link ↗ |
NCT03234907 NCT03234907 · Crohn's Disease The design is strong (randomized, quadruple-blind, placebo-controlled, adequately powered Phase 3 trial with a hard clinical endpoint), but the primary endpoint comparison was not statistically significant (p=0.347, CI crossing null), so per the grading rules a null/mixed result caps a well-designed trial at 'moderate' rather than 'strong'. Registry: NCT03234907 | 3 | Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 2020-08-14 | Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) | Partial signal | link ↗ |
NCT02038920 NCT02038920 · Crohn's Disease Design was randomized, quadruple-blinded, and placebo-controlled with a hard clinical endpoint (CDAI-based response/remission), but both co-primary endpoint comparisons failed to reach statistical significance (induction p=0.1448, maintenance p=0.1779), and the maintenance phase was severely underpowered (n=12 per arm). Per the grading rules, a well-designed trial with a null/mixed primary result is capped at moderate. Registry: NCT02038920 | 3 | Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response (Week 10); Maintenance Phase: Percentage of Participants With Clinical Remission (Week 60); Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs) (From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)); Number of Participants With TEAE Related to Body Weight (Weight Decreased) (From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)); Number of Participants With TEAE Related to Vital Signs (From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)); Number of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right] (From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)); Number of Participants With Markedly Abnormal Values of Laboratory Parameters Values (From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)) 2019-01-25 | Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response (Week 10): Induction Phase: Vedolizumab, 300 mg 26.6% (95% CI 17.268-37.720) vs Induction Phase: Placebo 16.7% (95% CI 9.184-26.813); p=0.1448 (Induction Phase: Vedolizumab, 300 mg vs Induction Phase: Placebo) | Partial signal | link ↗ |
GEMINI LTS NCT00790933 · Ulcerative Colitis, Crohn's Disease This meets the extension/rollover carve-out in the moderate definition (part a): the title, eligibility criteria, and population description explicitly state participants continued from four completed prior randomized controlled trials (with NCT numbers cited), making this a genuine open-label extension rather than a de-novo uncontrolled trial, despite lacking randomization/blinding/comparator itself. Registry: NCT00790933 | 3 | Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to approximately 8.5 years)); Number of Participants With Markedly Abnormal Safety Laboratory Findings (From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)); Percentage of Participants With at Least One Clinically Significant Mean Change Over Time in Vital Sign Measurements (From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)); Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) Findings (From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)); Time to Major Inflammatory Bowel Disease (IBD) - Related Events (Baseline (Prior to first dose of study drug in C13008) up to end of study (approximately up to 8.5 years)); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 28 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 52 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 76 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 100 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 124 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 148 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 172 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 196 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 248 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 300 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300); Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 352 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352); Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 28 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28); Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 28 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28); Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 52 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 52 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52); Change From Baseline in Short Form-36 (SF-36) Physical Component at Week 76 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 76 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76); Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 100 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 100 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100); Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 124 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124); Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 124 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124); Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 148 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 148 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148); Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 172 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172); Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 172 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172); Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 196 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 196 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196); Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 248 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 248 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248); Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 300 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 300 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300); Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 352 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352); Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 352 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 28 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 28 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 52 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 52 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 76 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 76 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 100 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 100 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 124 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 124 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 148 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 148 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 172 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 172 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 196 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 196 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 248 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 248 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 300 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300); Change From Baseline in EuroQol 5D Health States (EQ-5D) Visual Analog Scale (VAS) Score at Week 300 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 352 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352); Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 352 (Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352) 2017-10-31 | Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to approximately 8.5 years)): Vedolizumab 300 mg (UC) — TEAEs: 93 percentage of participants; SAEs: 31 percentage of participants | Vedolizumab 300 mg (CD) — TEAEs: 96 percentage of participants; SAEs: 41 percentage of participants | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (34)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (7)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 2/3 (1)
What this study did
Appears in other studies (5)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1 (1)
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other α4β7 integrin drugs
SPY001, Trosunilimab, Zotemtegrast. Compare all 4 α4β7 integrin drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vedolizumab (Entyvio): this drug | Approved | Monoclonal antibody | α4β7 integrin | Reliable signal | NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg) NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001). | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Balsalazide Disodium (Colazal) | ApprovedUS marketing discontinued | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide (Uceris Rectal Foam) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Budesonide MMX (Uceris) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed | |
| Dexamethasone | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Etrasimod (Velsipity) | Approved | Small molecule | S1P receptor | Reliable signal | NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo) | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance) | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints | |
| Hydrocortisone (Cortenema) | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Hydrocortisone Acetate (Cortifoam) | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | Weak signal | NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9% NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%) | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Zymfentra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Apriso) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Canasa) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Lialda) | Approved | Small molecule | Aminosalicylate | Reliable signal | NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants | |
| Mesalamine (Pentasa) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Rowasa) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5) NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W) | |
| Olsalazine (Dipentum) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Ozanimod (Zeposia) | Approved | Small molecule | S1P receptor | Reliable signal | NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo. | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | INSPIRE/COMMAND: clinical remission + endoscopic improvement met NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV) | |
| Sulfasalazine | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | Reliable signal | NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo) NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID) | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo) NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | Reliable signal | NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV) NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders. | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Asacol HD) | US approval withdrawn | Small molecule | Aminosalicylate | Partial signal | No reviewed efficacy summary in this indication | |
| Afimkibart | Phase 3 | Monoclonal antibody | TL1A | Partial signal | NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed | |
| Duvakitug | Phase 3 | Monoclonal antibody | TL1A | Partial signal | NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. | |
| Icotrokinra (Icotyde) | Phase 3 | Peptide | IL-23 receptor | Reliable signal | NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001) | |
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Mufemilast | Phase 3 | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| Obefazimod | Phase 3 | Small molecule | miR-124 | Reliable signal | NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001 NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%) | |
| Ponesimod | Phase 3 | Small molecule | S1P receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 3 | Monoclonal antibody | TL1A | Reliable signal | NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37) | |
| AC-101 | Phase 2 | Small molecule | RIPK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ALTB-268 | Phase 2 | Monoclonal antibody | PSGL-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Amiselimod | Phase 2 | Small molecule | S1P receptor | Reliable signal | NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) | |
| ATH-063 | Phase 2 | Small molecule | G9A (EHMT2) | Weak signal | Featured results are safety only in this race | |
| HRS-7085 | Phase 2 | Small molecule | NCBP1/NCBP2 (nuclear cap-binding complex) | Weak signal | No reviewed efficacy summary in this indication | |
| IPG11406 | Phase 2 | Small molecule | EBI2 | Weak signal | Featured results are safety only in this race | |
| MT-201 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| MT-501 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Omilancor | Phase 2 | Small molecule | LANCL2 | Partial signal | NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7% | |
| SPY001 | Phase 2 | Monoclonal antibody | α4β7 integrin | not yet graded | No reviewed efficacy summary in this indication | |
| Trosunilimab | Phase 2(overall) | Monoclonal antibody | α4β7 integrin | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Zotemtegrast | Phase 2 | Small molecule | α4β7 integrin | Weak signal | NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18) | |
| ICG318 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Remestemcel-L (Ryoncil) | Phase 1/2 | Cell therapy | Allogeneic MSC therapy | not yet graded | No reviewed efficacy summary in this indication | |
| BDHK-2009 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| ExoFlo | Phase 1 | Cell therapy | MSC-derived exosomes | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 72 furthest-along competitors are listed; 43 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Entyvio (vedolizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (12)
May 2027 (1)
What to watch
June 2027 (2)
July 2027 (2)
August 2027 (1)
What to watch
September 2027 (2)
October 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (5)
April 2028 (1)
What to watch
May 2028 (1)
What to watch
July 2028 (1)
What to watch
October 2028 (2)
What to watch
What to watch
2029 (1)
January 2029 (1)
What to watch
2030 (5)
January 2030 (1)
March 2030 (1)
What to watch
June 2030 (1)
What to watch
August 2030 (1)
What to watch
December 2030 (1)
What to watch
2033 (1)
February 2033 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent